3-V Bioscience-2640
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 3-V Bioscience-2640, covering 2023-04-20 to 2023-04-20. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome [Phase 1, Phase 2]